Search Videos by Topic or Participant
Browse by Series:

Making EGFR-Positive NSCLC a Chronic Disease

Lecia V. Sequist, MD, MPH, Harvard and Corey J. Langer, MD, University Pennsylvania
Published: Thursday, Apr 30, 2015
\
For High-Definition, Click
With the array of effective treatment options available, It may be realistic to expect that EGFR-mutant non-small cell lung cancer (NSCLC) may evolve into a chronic disease, Mark A. Socinski, MD, hopes. At this point, there are three-generations of successful agents, with the latest iteration showing promise in hard to treat patient populations. 

As research continues to explore treatment options, combination therapies are beginning to surface for patients with EGFR-mutant NSCLC, including EGFR TKIs with immune checkpoint inhibitors. Although positive, patients with EGFR-positive NSCLC represent a minority in the overall lung cancer population. Ideally, similar results could be duplicated in patients with pan-wild-type lung cancer, suggests Socinski.
 
Slider Left
Slider Right
\
For High-Definition, Click
With the array of effective treatment options available, It may be realistic to expect that EGFR-mutant non-small cell lung cancer (NSCLC) may evolve into a chronic disease, Mark A. Socinski, MD, hopes. At this point, there are three-generations of successful agents, with the latest iteration showing promise in hard to treat patient populations. 

As research continues to explore treatment options, combination therapies are beginning to surface for patients with EGFR-mutant NSCLC, including EGFR TKIs with immune checkpoint inhibitors. Although positive, patients with EGFR-positive NSCLC represent a minority in the overall lung cancer population. Ideally, similar results could be duplicated in patients with pan-wild-type lung cancer, suggests Socinski.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x